AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
perflutren 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| perfluorinated compounds used as blood substitutes and/or diagnostic agents | 2104 | 76-19-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Perflutren lipid microspheres exhibit lower acoustic impedance than blood and enhance the intrinsic backscatter of blood. These physical acoustic properties of activated perflutren provide contrast enhancement of the left ventricular chamber and aid delineation of the left ventricular endocardial border during echocardiography.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| Vd (Volume of distribution) | 1.60 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 590.71 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 0.02 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,AKT2,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,GRK2,GSK3B,IKBKB,ITK,JAK2,JAK3,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK12,MAPK7,MAPK9,MAPKAPK2,MET,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CD,PIK3CG,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ZAP70 | 55 | |||
| kinase-selectivity-class | AXL,GRK2,PDK1,PDK2,PIK3CD,PIK3CG | 6 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| July 31, 2001 | FDA | LANTHEUS MEDCL |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Back pain | 1090.28 | 54.33 | 383 | 2195 | 316792 | 90309077 |
| Muscle spasms | 213.67 | 54.33 | 115 | 2463 | 251768 | 90374101 |
| Flushing | 200.41 | 54.33 | 80 | 2498 | 88411 | 90537458 |
| Dyspnoea | 155.86 | 54.33 | 155 | 2423 | 880800 | 89745069 |
| Contrast media reaction | 113.11 | 54.33 | 21 | 2557 | 1230 | 90624639 |
| Neck pain | 110.22 | 54.33 | 57 | 2521 | 113906 | 90511963 |
| Chest pain | 106.26 | 54.33 | 81 | 2497 | 319564 | 90306305 |
| Pain in extremity | 71.09 | 54.33 | 75 | 2503 | 450454 | 90175415 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Back pain | 921.40 | 60.90 | 312 | 1679 | 141464 | 42477880 |
| Muscle spasms | 284.71 | 60.90 | 117 | 1874 | 85927 | 42533417 |
| Flushing | 117.15 | 60.90 | 49 | 1942 | 36979 | 42582365 |
| Urticaria | 109.75 | 60.90 | 58 | 1933 | 73978 | 42545366 |
| Neck pain | 99.20 | 60.90 | 41 | 1950 | 29973 | 42589371 |
| Anaphylactic reaction | 97.65 | 60.90 | 45 | 1946 | 42698 | 42576646 |
| Contrast media reaction | 81.51 | 60.90 | 17 | 1974 | 1099 | 42618245 |
| Pain in extremity | 76.35 | 60.90 | 60 | 1931 | 150544 | 42468800 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Back pain | 1813.18 | 59.44 | 634 | 3749 | 370362 | 110214554 |
| Muscle spasms | 466.89 | 59.44 | 224 | 4159 | 277933 | 110306983 |
| Flushing | 303.03 | 59.44 | 124 | 4259 | 104612 | 110480304 |
| Contrast media reaction | 183.93 | 59.44 | 37 | 4346 | 2361 | 110582555 |
| Neck pain | 175.10 | 59.44 | 89 | 4294 | 123041 | 110461875 |
| Dyspnoea | 164.33 | 59.44 | 209 | 4174 | 1106663 | 109478253 |
| Pain in extremity | 130.98 | 59.44 | 126 | 4257 | 486992 | 110097924 |
| Chest pain | 117.73 | 59.44 | 106 | 4277 | 376269 | 110208647 |
| Anaphylactic reaction | 115.77 | 59.44 | 66 | 4317 | 114234 | 110470682 |
| Flank pain | 100.89 | 59.44 | 37 | 4346 | 23093 | 110561823 |
| Urticaria | 98.04 | 59.44 | 89 | 4294 | 318768 | 110266148 |
| Unresponsive to stimuli | 93.12 | 59.44 | 47 | 4336 | 63743 | 110521173 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | V08DA01 | VARIOUS CONTRAST MEDIA ULTRASOUND CONTRAST MEDIA Ultrasound contrast media |
| ATC | V08DA04 | VARIOUS CONTRAST MEDIA ULTRASOUND CONTRAST MEDIA Ultrasound contrast media |
| FDA MoA | N0000010259 | Ultrasound Contrast Activity |
| MeSH PA | D003287 | Contrast Media |
| MeSH PA | D064907 | Diagnostic Uses of Chemicals |
| FDA EPC | N0000175864 | Contrast Agent for Ultrasound Imaging |
| CHEBI has role | CHEBI:35554 | cardiovascular drug |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
Related Drugs by ATC class:
V08DA Ultrasound contrast media 4 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Echocardiography | indication | 40701008 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 13.04MG/2ML (6.52MG/ML) | DEFINITY | LANTHEUS MEDCL | N021064 | July 31, 2001 | RX | INJECTABLE | INTRAVENOUS | 10583207 | Dec. 28, 2035 | METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING |
| 13.04MG/2ML (6.52MG/ML) | DEFINITY RT | LANTHEUS MEDCL | N021064 | Nov. 17, 2020 | RX | INJECTABLE | INTRAVENOUS | 10583207 | Dec. 28, 2035 | METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING |
| 13.04MG/2ML (6.52MG/ML) | DEFINITY RT | LANTHEUS MEDCL | N021064 | Nov. 17, 2020 | RX | INJECTABLE | INTRAVENOUS | 11395856 | Dec. 28, 2035 | METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING |
| 13.04MG/2ML (6.52MG/ML) | DEFINITY | LANTHEUS MEDCL | N021064 | July 31, 2001 | RX | INJECTABLE | INTRAVENOUS | 10583208 | March 16, 2037 | METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING |
| 13.04MG/2ML (6.52MG/ML) | DEFINITY RT | LANTHEUS MEDCL | N021064 | Nov. 17, 2020 | RX | INJECTABLE | INTRAVENOUS | 10583208 | March 16, 2037 | METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING |
| 13.04MG/2ML (6.52MG/ML) | DEFINITY | LANTHEUS MEDCL | N021064 | July 31, 2001 | RX | INJECTABLE | INTRAVENOUS | 11266750 | March 16, 2037 | METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING |
| 13.04MG/2ML (6.52MG/ML) | DEFINITY RT | LANTHEUS MEDCL | N021064 | Nov. 17, 2020 | RX | INJECTABLE | INTRAVENOUS | 11266750 | March 16, 2037 | METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING |
| 13.04MG/2ML (6.52MG/ML) | DEFINITY | LANTHEUS MEDCL | N021064 | July 31, 2001 | RX | INJECTABLE | INTRAVENOUS | 11529431 | March 16, 2037 | METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING |
| 13.04MG/2ML (6.52MG/ML) | DEFINITY RT | LANTHEUS MEDCL | N021064 | Nov. 17, 2020 | RX | INJECTABLE | INTRAVENOUS | 11529431 | March 16, 2037 | METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING |
| 13.04MG/2ML (6.52MG/ML) | DEFINITY | LANTHEUS MEDCL | N021064 | July 31, 2001 | RX | INJECTABLE | INTRAVENOUS | 11857646 | March 16, 2037 | METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING |
| 13.04MG/2ML (6.52MG/ML) | DEFINITY RT | LANTHEUS MEDCL | N021064 | Nov. 17, 2020 | RX | INJECTABLE | INTRAVENOUS | 11857646 | March 16, 2037 | METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING |
| 13.04MG/2ML (6.52MG/ML) | DEFINITY | LANTHEUS MEDCL | N021064 | July 31, 2001 | RX | INJECTABLE | INTRAVENOUS | 11925695 | March 16, 2037 | METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING |
| 13.04MG/2ML (6.52MG/ML) | DEFINITY RT | LANTHEUS MEDCL | N021064 | Nov. 17, 2020 | RX | INJECTABLE | INTRAVENOUS | 11925695 | March 16, 2037 | METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING |
| 13.04MG/2ML (6.52MG/ML) | DEFINITY | LANTHEUS MEDCL | N021064 | July 31, 2001 | RX | INJECTABLE | INTRAVENOUS | 12161730 | March 16, 2037 | METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING |
| 13.04MG/2ML (6.52MG/ML) | DEFINITY RT | LANTHEUS MEDCL | N021064 | Nov. 17, 2020 | RX | INJECTABLE | INTRAVENOUS | 12161730 | March 16, 2037 | METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING |
| 13.04MG/2ML (6.52MG/ML) | DEFINITY | LANTHEUS MEDCL | N021064 | July 31, 2001 | RX | INJECTABLE | INTRAVENOUS | 9789210 | March 16, 2037 | METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING |
| 13.04MG/2ML (6.52MG/ML) | DEFINITY RT | LANTHEUS MEDCL | N021064 | Nov. 17, 2020 | RX | INJECTABLE | INTRAVENOUS | 9789210 | March 16, 2037 | METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING |
| 13.04MG/2ML (6.52MG/ML) | DEFINITY | LANTHEUS MEDCL | N021064 | July 31, 2001 | RX | INJECTABLE | INTRAVENOUS | 10588988 | May 4, 2037 | METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING |
| 13.04MG/2ML (6.52MG/ML) | DEFINITY RT | LANTHEUS MEDCL | N021064 | Nov. 17, 2020 | RX | INJECTABLE | INTRAVENOUS | 10588988 | May 4, 2037 | METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| 4024282 | VUID |
| N0000148772 | NUI |
| D01738 | KEGG_DRUG |
| 4021302 | VANDF |
| 4021353 | VANDF |
| 4024282 | VANDF |
| C0937858 | UMLSCUI |
| CHEBI:31980 | CHEBI |
| CHEMBL1663 | ChEMBL_ID |
| DB00556 | DRUGBANK_ID |
| 6432 | PUBCHEM_CID |
| C042852 | MESH_SUPPLEMENTAL_RECORD_UI |
| 7932 | INN_ID |
| CK0N3WH0SR | UNII |
| 283753 | RXNORM |
| 16500 | MMSL |
| d04796 | MMSL |
| 009302 | NDDF |
| 409291008 | SNOMEDCT_US |
| 409292001 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| OptisonPerflutren Protein-Type A Microspheres | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0407-2707 | INJECTION, SOLUTION | 0.22 mg | INTRAVENOUS | NDA | 28 sections |
| Definity | HUMAN PRESCRIPTION DRUG LABEL | 1 | 11994-011 | INJECTION, SUSPENSION | 6.52 mg | INTRAVENOUS | NDA | 28 sections |
| DEFINITY RT | HUMAN PRESCRIPTION DRUG LABEL | 1 | 11994-017 | INJECTION, SUSPENSION | 6.52 mg | INTRAVENOUS | NDA | 28 sections |